Pfizer (NYSE:PFE) Confirms Renewed Attempt To Acquire AstraZeneca. Pfizer Inc. revealed that it was looking to acquire British pharmaceutical company, AstraZeneca, for $100 billion. Pfizer Inc. (NYSE:PFE) shares after opening at $31.08 moved to $31.58 on last trade day and at the end of the day closed at $31.15. Company price to sales ratio in past twelve months was calculated as 3.86 and price to cash ratio as 6.15. Pfizer Inc. (NYSE:PFE) showed a positive weekly performance of 1.43%.
Gilead Sciences, Inc. (NASDAQ:GILD) says its drug gives hepatitis C patients more cost-effective cure. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.68% in last trading session and ended the day on $79.02. GILD return on equity ratio is recorded as 38.90% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 57.60%.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) announced Thursday morning that its Phase 3 study of the combination of MM-398 with 5-fluorouracil and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) shares moved up 59.23% in last trading session and was closed at $6.99, while trading in range of $6.55 – $7.65. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) year to date (YTD) performance is 31.14%.
One of the global leaders in pharmaceuticals, Israel-based Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) recently revealed their sponsorship of 14 abstracts of studies on their well-established multiple sclerosis treatments COPAXONE® and laquinimod. The abstracts were presented at the 66th annual American Academy of Neurology (AAN) conference in Philadelphia, and, according to Teva, successfully added recently developed information on the clinical benefits of a thrice-a-week COPAXONE® 40mg/mL regimen for multiple sclerosis patients. The studies also shed light on its effectiveness, safety, and tolerability. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) weekly performance is 2.27%. On last trading day company shares ended up $50.97. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 2.13%. Analysts mean target price for the company is $55.36.